Genscript Biotech (HK:1548)
:1548
Want to see HK:1548 full AI Analyst Report?
1548 Stock Chart & Stats
HK$13.76
-HK$0.07(-0.74%)
At close: 4:00 PM EST
HK$13.76
-HK$0.07(-0.74%)
Day’s Range― - ―
52-Week RangeHK$10.36 - HK$19.40
Previous CloseN/A
Volume5.33M
Average Volume (3M)11.61M
Market Cap
HK$28.49B
Enterprise ValueHK$4.00B
Total Cash (Recent Filing)HK$843.01M
Total Debt (Recent Filing)HK$523.15M
Price to Earnings (P/E)―
Beta1.07
Next Earnings
Aug 17, 2026EPS Estimate
-0.08Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.25
Shares Outstanding2,188,137,500
10 Day Avg. Volume8,707,016
30 Day Avg. Volume11,605,265
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.87
Price to Sales (P/S)3.60
P/FCF Ratio14.31
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$19.05Price Target Upside38.42% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)0.03
Revenue Forecast (FY)HK$813.48M
Bulls Say, Bears Say
Bulls Say
Improved Top-line And Operating MarginsA 74% revenue rebound combined with high gross (≈57.7%) and EBIT (≈26.6%) margins indicates underlying demand and operational leverage in GenScript’s core research and CDMO services. These durable margin levels suggest structurally profitable service lines if client program flows and pricing persist.
Strengthening Cash GenerationA return to positive operating cash flow and material free cash flow demonstrates improved ability to self-fund working capital, capex and growth initiatives. If sustained, stronger cash conversion reduces reliance on external funding and supports durable investment in capacity for biologics and CDMO services.
Manageable Leverage And Equity BaseLower debt-to-equity and a sizable equity base provide financial flexibility to fund capex and absorb cyclicality in R&D outsourcing. Improved leverage enhances resilience across biotech cycles, supporting long-term capacity investments and maintaining service delivery for large client programs.
Bears Say
Highly Volatile Net ResultsExtreme swings in net results undermine earnings predictability and make long-term planning and return expectations uncertain. Such volatility may reflect one-offs, timing of collaboration items or accounting variability, reducing the reliability of reported profitability across planning horizons.
Inconsistent Historical Cash FlowPrior multi-year cash burn followed by a one-year rebound indicates cash generation is sensitive to project timing and business mix. This inconsistency increases the risk that capital needs re-emerge during slower program cycles, challenging durable self-funding of growth and margin expansion.
Revenue Visibility Tied To Client Program TimingGenScript’s revenue is lumpy and linked to customers advancing programs, utilization of manufacturing capacity, and contributions from subsidiaries/partners. This structural dependency reduces revenue predictability and can produce multi-quarter swings tied to partners’ development milestones rather than steady recurring demand.
Genscript Biotech News
1548 FAQ
What was Genscript Biotech’s price range in the past 12 months?
Genscript Biotech lowest stock price was HK$10.36 and its highest was HK$19.40 in the past 12 months.
What is Genscript Biotech’s market cap?
Genscript Biotech’s market cap is HK$28.49B.
When is Genscript Biotech’s upcoming earnings report date?
Genscript Biotech’s upcoming earnings report date is Aug 17, 2026 which is in 88 days.
How were Genscript Biotech’s earnings last quarter?
Genscript Biotech released its earnings results on Mar 16, 2026. The company reported -HK$1.801 earnings per share for the quarter, missing the consensus estimate of -HK$0.235 by -HK$1.566.
Is Genscript Biotech overvalued?
According to Wall Street analysts Genscript Biotech’s price is currently Undervalued.
Does Genscript Biotech pay dividends?
Genscript Biotech pays a Notavailable dividend of HK$0.012 which represents an annual dividend yield of N/A. See more information on Genscript Biotech dividends here
What is Genscript Biotech’s EPS estimate?
Genscript Biotech’s EPS estimate is -0.08.
How many shares outstanding does Genscript Biotech have?
Genscript Biotech has 2,188,137,500 shares outstanding.
What happened to Genscript Biotech’s price movement after its last earnings report?
Genscript Biotech reported an EPS of -HK$1.801 in its last earnings report, missing expectations of -HK$0.235. Following the earnings report the stock price went up 1.262%.
Which hedge fund is a major shareholder of Genscript Biotech?
Currently, no hedge funds are holding shares in HK:1548
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Genscript Biotech Stock Smart Score
Company Description
Genscript Biotech
Genscript Biotech Corporation, an investment holding company, engages in the manufacture and sale of life science research products and services in North America, Europe, the People's Republic of China, Japan, the other Asia Pacific regions, and internationally. It operates through four segments: Life Science Services and Products, Biologics Development Services, Industrial Synthetic Biology Products, and Cell Therapy. The Life Science Services and Products segment provides research services in various categories, including gene synthesis and molecular cloning, oligonucleotide synthesis, protein engineering, peptide synthesis, antibody development, molecular diagnostics tools, and genome editing materials for use in basic biology studies, pharmaceutical and drug discovery, disease diagnostics and vaccine, agriculture, environmental studies, and food industry. The Biologics Development Services segment offers various services, such as antibody drug discovery, antibody drug pre-clinical and clinical development, plasmid and virus pre-clinical development, and plasmid and virus clinical development for therapeutic antibodies, as well as gene and cell therapy development and biologics discovery and development services for pharmaceutical, biotech, government, and academic customers. The Industrial Synthetic Biology Products segment constructs non-pathogenic microbial strains; and develops and produces industrial enzymes for food processing, feed, pharmaceutical, and chemical industries. The Cell Therapy segment discovers and develops chimeric antigen receptor T-cell therapies for the treatment of liquid and solid tumors. Genscript Biotech Corporation was founded in 2002 and is headquartered in Nanjing, the People's Republic of China.
1548 Company Deck
1548 Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant revenue growth across all segments, strong performance of Legend Biotech's CAR-T product, and a robust cash position. However, the Group faced challenges with net losses due to Legend Biotech, temporary impacts on gross margins, and capacity issues in ProBio. Despite these challenges, the positive achievements and growth outweigh the difficulties.View all HK:1548 earnings summaries1548 Stock 12 Month Forecast
Average Price Target
HK$19.05
▲(38.42% Upside)
Technical Analysis
Wuxi Biologics (Cayman)
―
Pharmaron Beijing Co., Ltd. Class H
―
Frontage Holdings Corp.
―
Viva Biotech Holdings
―
Asymchem Laboratories (Tianjin) Co., Ltd. Class H
―
Options Prices
Currently, No data available
---